Panacea Biotec

PANACEABIO02 May 2024

Pharmaceuticals

₹

-1.20 (-0.85%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Panacea Biotec

Panacea Biotec

Pharmaceuticals

PANACEABIO02 May 2024

₹

-1.20 (-0.85%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
13-Jan-2003	S	Stock split of existing equity share from every one existing equity share of Rs.10/- each into ten equity shares of Re.1/- each. Reduced paid-up value - Re.1/- Reduced paid-up value w.e.f. - 03/02/2003.	11-Feb-2003
13-May-2011	D	Panacea Biotec Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 13, 2011, inter alia, has recommended dividend of Re. 0.75 (75%) each on Equity Shares of the Company, for the financial year 2010-11. The total amount of dividend payable, if approved by Shareholders in their ensuing Annual General Meeting, shall be Rs. 45.9 million, excluding dividend distribution tax.	19-Sep-2011
07-May-2010	D	Panacea Biotec Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 07, 2010, inter alia, has recommended dividend of Re. 0.25 (25%) each on Equity Shares of the Company, for the financial year 2009-10. The total amount of dividend payable, if approved by Shareholders, shall be Rs. 16.7 million, excluding dividend distribution tax.	16-Sep-2010
26-Jun-2008	D	Panacea Biotec Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 26, 2008, inter alia, has recommended dividend @ 100% (i.e. Re 1/- per share) on Equity Shares of the Company, for the financial year 2007-08.	19-Sep-2008
14-Jun-2007	D	100% Dividend	21-Sep-2007
12-Aug-2005	D	150% Dividend	12-Aug-2005
12-Mar-2024	BC	Please find enclosed copy of the Postal Ballot Notice along with Annexure thereto being sent to the shareholders through email only for the purpose of obtaining their approval on the Special Resoluti	11-Apr-2024
13-Feb-2024	BC	2. Re-appointment of Mr. Bhupinder Singh as a Non-Executive Independent Director Intimation with respect to Re-appointment of Mr. Bhupinder Singh as Non-Executive Independent Director and appointm	08-Apr-2024
01-Apr-2024	BC	We would like to inform you that Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narsimhan have completed their second and final terms of five consecutive years as Indepe	31-Mar-2024
13-Feb-2024	BC	3. Appointment of Mrs. Ambika Sharma as an additional director in the capacity of Non-Executive Independent Director	14-Feb-2024
30-Jan-2024	BC	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited F	13-Feb-2024

No Rights has been declared by PANACEABIO

Book Closure

Record Date	Split Date	Purpose
11-Apr-2024	01 Jan'1900	Please find enclosed copy of the Postal Ballot Notice along with Annexure thereto being sent to the shareholders through email only for the purpose of obtaining their approval on the Special Resoluti
08-Apr-2024	-	2. Re-appointment of Mr. Bhupinder Singh as a Non-Executive Independent Director Intimation with respect to Re-appointment of Mr. Bhupinder Singh as Non-Executive Independent Director and appointm
31-Mar-2024	-	We would like to inform you that Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narsimhan have completed their second and final terms of five consecutive years as Indepe
14-Feb-2024	-	3. Appointment of Mrs. Ambika Sharma as an additional director in the capacity of Non-Executive Independent Director
13-Feb-2024	-	PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the Standalone and Consolidated Unaudited F

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Panacea Biotec Ltd ₹140.10(-1.20/-0.85%)	140.10	-1.20	858.12	14.32	0.00	2.60
Astrazeneca Pharma India Ltd ₹5,333.85(-7.40/-0.14%)	5,333.85	-7.40	13,334.63	67.79	83.60	20.36
Bliss GVS Pharma Ltd ₹129.20(+5.50/4.45%)	129.20	+5.50	1,352.61	67.42	19.82	1.38
Cipla Ltd ₹1,419.55(+18.35/1.31%)	1,419.55	+18.35	114,613.75	54.95	34.85	4.43
Amrutanjan Health Care Ltd ₹786.60(+88.65/12.70%)	786.60	+88.65	2,274.11	29.81	51.68	8.68
Abbott India Ltd ₹26,604.35(+188.60/0.71%)	26,604.35	+188.60	56,534.24	18.89	49.35	18.18

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	95.23	94.59	89.41	75.02	71.97	48.74
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	95.23	94.59	89.41	75.02	71.97	48.74
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	3.05	2.13	3.34	10.27	9.71	7.92
Total Income	98.28	96.72	92.75	85.29	81.68	56.66
Total Expenditure	88.59	84.63	82.60	71.59	59.68	55.06
PBIDT	9.69	12.09	10.15	13.70	22.00	1.60
Interest	3.41	3.55	3.46	2.70	2.68	2.21
PBDT	6.28	8.54	6.69	11.00	19.32	-0.61
Depreciation	5.21	5.34	5.40	5.90	6.08	6.24
Tax	0.64	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	24.79	0.00	0.00
Reported Profit After Tax	0.43	3.20	1.29	-19.69	13.24	-6.85
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	0.43	3.20	1.29	-19.69	13.24	-6.85

EPS (Unit Curr.)	0.07	0.52	0.21	-3.21	2.16	-1.12
EPS (Adj) (Unit Curr.)	0.07	0.52	0.21	-3.21	2.16	-1.12
Calculated EPS (Unit Curr.)	0.07	0.52	0.21	-3.21	2.16	-1.12
Calculated EPS (Adj) (Unit Curr.)	0.07	0.52	0.21	-3.21	2.16	-1.12
Calculated EPS (Ann.) (Unit Curr.)	0.28	2.09	0.84	-12.85	8.64	-4.47
Calculated EPS (Adj) (Ann.) (Unit Curr.)	0.28	2.09	0.84	-12.85	8.64	-4.47
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	6.13	6.13	6.13	6.13	6.13	6.13
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	1.00	1.00	1.00	1.00	1.00	1.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	10.18	12.78	11.35	18.26	30.57	3.28
PBDTM(%)	6.59	9.03	7.48	14.66	26.84	-1.25
PATM(%)	0.45	3.38	1.44	-26.25	18.40	-14.05

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	150.50	143.02	129.19	128.93	115.20	105.12
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	150.50	143.02	129.19	128.93	115.20	105.12
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	8.46	6.00	33.82	34.44	41.71	38.22
Total Income	158.96	149.02	163.01	163.37	156.91	143.34
Total Expenditure	150.65	146.58	139.50	134.60	123.84	108.96
PBIDT	8.31	2.44	23.51	28.77	33.07	34.38
Interest	0.85	0.91	1.00	1.05	0.96	1.18
PBDT	7.46	1.53	22.51	27.72	32.11	33.20
Depreciation	9.11	9.31	9.48	9.51	9.67	9.89
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.62	0.00	0.00	2.56	0.00	0.00
Deferred Tax	-0.07	0.51	2.05	28.33	3.07	7.61
Reported Profit After Tax	-2.20	-8.29	10.98	-12.68	19.37	15.70
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	-2.20	-8.29	10.98	-12.68	19.37	15.70

Extra-ordinary Items	2.16	2.59	25.69	-11.51	24.70	20.16
Adjusted Profit After Extra-ordinary item	-4.36	-10.88	-14.71	-1.17	-5.33	-4.46

EPS (Unit Curr.)	-0.37	-1.35	1.79	-2.07	3.16	2.56
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	6.13	6.13	6.13	6.13	6.13	6.13

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	5.52	1.71	18.20	22.31	28.71	32.71
PBDTM(%)	4.96	1.07	17.42	21.50	27.87	31.58
PATM(%)	-1.46	-5.80	8.50	-9.83	16.81	14.94

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	6.13	6.13	6.13	6.13	6.13	15.59
Reserves Total	297.87	387.32	480.39	832.82	402.71	372.33
Equity Share Warrants	0.00	0.00	0.00	32.00	0.00	0.00
Equity Application Money	21.65	21.65	21.65	21.79	9.64	9.64
Total Shareholders Funds	325.65	415.10	508.17	892.74	418.48	397.56
Secured Loans	0.24	0.29	5.05	12.44	604.57	906.96
Unsecured Loans	102.22	83.87	60.03	54.80	84.11	53.27
Total Debt	102.46	84.16	65.08	67.24	688.68	960.23
Total Liabilities	428.11	499.26	573.25	959.98	1107.16	1357.79
APPLICATION OF FUNDS :
Gross Block	909.49	907.86	893.02	905.42	813.95	1542.55
Less : Accumulated Depreciation	474.13	453.83	428.77	406.14	317.52	651.62
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	435.36	454.03	464.25	499.28	496.43	890.93
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	27.85	0.88	12.97	3.74	3.10	37.16
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.27	0.27	0.27	2.55	2.54	344.88
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	116.10	129.25	87.04	99.23	42.51	149.10
Sundry Debtors	12.27	23.32	35.29	17.69	25.20	142.27
Cash and Bank	43.25	42.69	88.96	60.61	7.85	11.79
Loans and Advances	27.52	53.57	81.26	436.80	840.55	50.50
Total Current Assets	199.14	248.82	292.55	614.32	916.10	353.65
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	224.16	217.84	192.08	157.44	311.05	279.50
Provisions	28.74	28.86	4.44	3.10	9.66	6.79
Total Current Liabilities	252.89	246.70	196.52	160.54	320.72	286.29
Net Current Assets	-53.76	2.12	96.03	453.77	595.39	67.36
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	46.02	72.09	0.00	135.13	166.64	203.13
Deferred Tax Liability	70.82	72.09	0.00	133.68	147.43	181.14
Net Deferred Tax	-24.80	0.00	0.00	1.45	19.21	21.99
Total Assets	384.91	457.30	573.52	960.79	1116.68	1362.32
Contingent Liabilities	639.76	368.17	406.99	366.93	404.06	378.64

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	6.13	6.13	6.13	6.13	6.13	6.13
Reserves Total	815.82	848.86	-256.47	138.87	334.63	292.91
Equity Share Warrants	0.00	0.00	0.00	32.00	0.00	0.00
Equity Application Money	21.65	21.65	21.65	21.79	9.64	9.64
Total Shareholders Funds	843.60	876.64	-228.69	198.79	350.40	308.68
Minority Interest	-3.49	-2.98	-3.00	-3.04	-3.01	-2.95
Secured Loans	0.24	0.29	759.50	708.64	604.57	906.96
Unsecured Loans	19.98	33.87	60.03	33.55	41.93	33.79
Total Debt	20.22	34.16	819.53	742.19	646.50	940.75
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	58.69	74.74	225.05	129.48	43.75	30.83
Total Liabilities	919.02	982.56	812.89	1067.42	1037.64	1277.31
APPLICATION OF FUNDS :
Gross Block	1330.83	1317.48	1261.62	1274.64	1392.90	1605.84
Less: Accumulated Depreciation	730.88	695.41	652.92	617.25	587.34	656.87
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	599.95	622.07	608.70	657.39	805.56	948.97
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	42.32	17.26	34.42	24.01	22.51	39.93
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	13.49	5.07	0.07	5.58	5.33	7.28
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	202.09	212.72	174.14	147.69	81.43	334.21
Sundry Debtors	60.09	81.66	84.68	68.52	88.73	136.01
Cash and Bank	225.99	583.28	135.79	89.75	23.48	23.24
Loans and Advances	60.73	67.90	116.36	377.31	314.25	64.87
Total Current Assets	548.90	945.56	510.97	683.27	507.89	558.32
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	295.07	740.28	351.27	315.48	323.97	314.04
Provisions	36.70	36.03	13.37	7.41	13.92	6.95
Total Current Liabilities	331.77	776.32	364.65	322.89	337.89	320.99
Net Current Assets	217.13	169.24	146.32	360.38	170.00	237.33
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	79.89	127.44	120.28	135.63	167.22	219.22
Deferred Tax Liability	100.26	103.69	120.13	133.68	147.43	208.82
Net Deferred Tax	-20.37	23.75	0.15	1.95	19.79	10.40
Other Assets	66.50	145.16	23.23	18.11	14.45	33.40
Total Assets
Contingent Liabilities	639.76	368.17	406.99	366.93	404.06	378.64

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	5.33	8.66	14.92	4.96	6.52
Net Cash from Operating Activities	-10.74	-52.69	38.27	-82.86	107.16
Net Cash Used In Investing Activities	2.41	39.54	-37.32	-16.58	-10.27
Net Cash Used In Financing Activities	9.01	9.83	-7.20	109.39	-98.45
Net Inc./Dec In Cash And Cash Equivalents	0.67	-3.32	-6.26	9.96	-1.57
Cash And Cash Equivalents At End Of The Year	6.01	5.33	8.66	14.92	4.96

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

73.59%

FII Shareholding

0.27%

DII Shareholding

0.84%

Public Shareholding

25.30%

**Promoter pledged shareholding 73.59%

About Panacea Biotec Ltd

Panacea Biotec Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 858.12 crores. It has reported a sales of Rs. 95.23 crores and a net profit of Rs. 0.43 crores for the quarter ended December 2018. The company management includes Rajesh Jain, Rajesh Jain,Sandeep Jain,R L Narasimhan,N N Khamitkar,K M Lal,Vinod Goel,Manjula Upadhyay,Mukul Gupta,Ankesh Jain,BHUPINDER SINGH,Narotam Kumar Juneja (Panacea Biotec Ltd) among others.

Chairman

Rajesh Jain

Registered office

Ambala-Chandigarh Highway,,Lalru,Punjab,140501

FAX :

Background

Incorporation Year1984

Face Value₹1

Market Lot1

How to buy Panacea Biotec shares on nse?

To buy Panacea Biotec shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Panacea Biotec share price today?

The Panacea Biotec shares price on nse is Rs.140.1 today.

What is the market cap of Panacea Biotec shares on BSE ?

The company has a market capitalization of Rs.858.12Cr

What is the PE & PB ratio of Panacea Biotec shares ?

PE is 0 and PB is 2.6

What is the 52 Week High and Low of Panacea Biotec shares?

Panacea Biotec stock price high: Rs.202.2 Panacea Biotec stock price low: Rs.113.55